LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state

In luminal B tumors LATS2 depletion results in metabolic rewiring whereas LATS1 depletion promotes the expression of basal-like features. Deregulated activity of LArge Tumor Suppressor (LATS) tumor suppressors has broad implications on cellular and tissue homeostasis. We examined the consequences of down-regulation of either LATS1 or LATS2 in breast cancer. Consistent with their proposed tumor suppressive roles, expression of both paralogs was significantly down-regulated in human breast cancer, and loss of either paralog accelerated mammary tumorigenesis in mice. However, each paralog had a distinct impact on breast cancer. Thus, LATS2 depletion in luminal B tumors resulted in metabolic rewiring, with increased glycolysis and reduced peroxisome proliferator-activated receptor γ (PPARγ) signaling. Furthermore, pharmacological activation of PPARγ elicited LATS2-dependent death in luminal B-derived cells. In contrast, LATS1 depletion augmented cancer cell plasticity, skewing luminal B tumors towards increased expression of basal-like features, in association with increased resistance to hormone therapy. Hence, these two closely related paralogs play distinct roles in protection against breast cancer; tumors with reduced expression of either LATS1 or LATS2 may rewire signaling networks differently and thus respond differently to anticancer treatments.

[1]  I. Ellis,et al.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. , 2017, The American journal of pathology.

[2]  Y. Aylon,et al.  The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway , 2017, Cell Death and Differentiation.

[3]  G. Wahl,et al.  Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity , 2017, npj Breast Cancer.

[4]  E. Polley,et al.  Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer , 2017, Theranostics.

[5]  Zhengdong D. Zhang,et al.  Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model , 2017, BMC Genomics.

[6]  Michael B. Stadler,et al.  The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα , 2017, Nature.

[7]  Matthew V. Holt,et al.  The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity , 2016, Cell.

[8]  V. Rotter,et al.  Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. , 2016, Cold Spring Harbor perspectives in medicine.

[9]  B. Gumbiner,et al.  Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis , 2016, Mammalian Genome.

[10]  Zhi-hua Li,et al.  Luminal B breast cancer: patterns of recurrence and clinical outcome , 2016, Oncotarget.

[11]  Jeong-Hwan Kim,et al.  LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development , 2016, Nature Communications.

[12]  S. Friedman,et al.  The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation , 2016, Genes & development.

[13]  Doron Lancet,et al.  GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data , 2016, Omics : a journal of integrative biology.

[14]  Ron Rotkopf,et al.  RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer , 2016, Cell reports.

[15]  S. Bicciato,et al.  YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins , 2016, EMBO reports.

[16]  M. Jackson,et al.  Cancer Stem Cell Plasticity Drives Therapeutic Resistance , 2016, Cancers.

[17]  Gwendolyn M. Jang,et al.  Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. , 2015, Cell host & microbe.

[18]  S. Kucucuk,et al.  Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer , 2015, Medicine.

[19]  E. Domany,et al.  Down-regulation of LATS kinases alters p53 to promote cell migration , 2015, Genes & development.

[20]  G. Halder,et al.  MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway , 2015, Nature Communications.

[21]  Alexander Dobin,et al.  Mapping RNA‐seq Reads with STAR , 2015, Current protocols in bioinformatics.

[22]  Ying Zhou,et al.  Expression of LATS family proteins in ovarian tumors and its significance. , 2015, Human pathology.

[23]  Kun-Liang Guan,et al.  The emerging roles of YAP and TAZ in cancer , 2015, Nature Reviews Cancer.

[24]  M. Lazar,et al.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.

[25]  E. Iversen,et al.  A joint analysis of metabolomics and genetics of breast cancer , 2014, Breast Cancer Research.

[26]  Souhad El Akoum,et al.  PPAR Gamma at the Crossroads of Health and Disease: A Masterchef in Metabolic Homeostasis , 2014 .

[27]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[28]  Andrew J Ewald,et al.  A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis , 2014, Genes & development.

[29]  Andrew J. Ewald,et al.  Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program , 2013, Cell.

[30]  Xiaoxiang Hu,et al.  Lats2 Modulates Adipocyte Proliferation and Differentiation via Hippo Signaling , 2013, PloS one.

[31]  N. Inestrosa,et al.  Peroxisome Proliferator-Activated Receptor (PPAR) γ and PPARα Agonists Modulate Mitochondrial Fusion-Fission Dynamics: Relevance to Reactive Oxygen Species (ROS)-Related Neurodegenerative Disorders? , 2013, PloS one.

[32]  Kishore R. Sakharkar,et al.  Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology , 2013, Journal of drug targeting.

[33]  Shelley M Enger,et al.  Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[34]  R. Cardiff,et al.  Proliferative and Nonproliferative Lesions of the Rat and Mouse Mammary, Zymbal’s, Preputial, and Clitoral Glands , 2012, Toxicologic pathology.

[35]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[36]  Leandro Martínez,et al.  Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists , 2012, PloS one.

[37]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[38]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[39]  Byung-Chul Oh,et al.  Mammalian Ste20-Like Kinase and SAV1 Promote 3T3-L1 Adipocyte Differentiation by Activation of PPARγ , 2012, PloS one.

[40]  Ben Tran,et al.  Luminal-B breast cancer and novel therapeutic targets , 2011, Breast Cancer Research.

[41]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[42]  Valerie Speirs,et al.  Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.

[43]  I. Ellis,et al.  Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation? , 2011, The Journal of pathology.

[44]  Nicola Elvassore,et al.  Role of YAP/TAZ in mechanotransduction , 2011, Nature.

[45]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[46]  M. Oren,et al.  The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. , 2010, Genes & development.

[47]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[48]  A. Ashworth,et al.  BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. , 2010, Cell stem cell.

[49]  H. Brauch,et al.  Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation , 2010, Proceedings of the National Academy of Sciences.

[50]  Wei Zhang,et al.  PPARgamma activation induces autophagy in breast cancer cells. , 2009, The international journal of biochemistry & cell biology.

[51]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Network Boston.

[52]  H. Aburatani,et al.  The Peroxisome Proliferator-Activated Receptor γ/Retinoid X Receptor α Heterodimer Targets the Histone Modification Enzyme PR-Set7/Setd8 Gene and Regulates Adipogenesis through a Positive Feedback Loop , 2009, Molecular and Cellular Biology.

[53]  Janet Rossant,et al.  The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. , 2009, Developmental cell.

[54]  Jiang Shou,et al.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.

[55]  Jianmin Zhang,et al.  Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. , 2008, Cancer research.

[56]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[57]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[59]  M. Oren,et al.  A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. , 2006, Genes & development.

[60]  David Basiji,et al.  Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow. , 2006, Journal of immunological methods.

[61]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[62]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Esteban O. Mazzoni,et al.  The Growth Regulators warts/lats and melted Interact in a Bistable Loop to Specify Opposite Fates in Drosophila R8 Photoreceptors , 2005, Cell.

[64]  Thomas Benjamin,et al.  TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell Differentiation , 2005, Science.

[65]  Martin Fenner,et al.  Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer , 2005 .

[66]  Y. Miyoshi,et al.  Down-Regulation of LATS1 and LATS2 mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers , 2005, Clinical Cancer Research.

[67]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[69]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[70]  E. Williamson,et al.  A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. , 2000, Journal of the National Cancer Institute.

[71]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[72]  M. Sporn,et al.  A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .

[73]  B. Spiegelman,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[74]  W. Tao,et al.  Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction , 1999, Nature Genetics.

[75]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[76]  J Isola,et al.  Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Lehmann,et al.  The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .

[78]  G. Giamas,et al.  LATS2 is a modulator of estrogen receptor alpha. , 2013, Anticancer research.

[79]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[80]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[81]  P. Neven,et al.  Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .

[82]  S. Konduri,et al.  Estrogen Receptor- (cid:1) Binds p53 Tumor Suppressor Protein Directly and Represses Its Function , 2006 .

[83]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[84]  J. Pollard,et al.  Animal Model Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases , 2003 .

[85]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .